Vancouver, BC & Newton, MA - September 24, 2025 - Kapoose Creek Bio (KC Bio), a Canadian-based biotechnology company revolutionizing the discovery of first-in-class therapeutics from nature using AI, today announced a partnership agreement with Terrain Life Science, a Boston-based leader in clinical-grade spatial proteomics.
The collaboration will leverage Terrain’s advanced spatial proteomics platform to support the advancement of KC Bio’s lead therapeutic candidate, KCB-100, a novel small molecule in development for depression. The study will further validate the mechanism of action of KCB-100, a potent neuroplastic lead compound currently being optimized for oral dosing. The research aims to generate critical mechanistic and biomarker data to support the development of KCB-100 as a novel therapy for depression, while also exploring potential applications in neurodegenerative diseases of aging, such as Alzheimer’s.
“We are excited to partner with Terrain to leverage their cutting-edge spatial proteomics platform to advance KCB-100,” said Dr. Eric Brown, CEO, Kapoose Creek Bio. “This collaboration will provide critical insights into the efficacy and mechanism of this potent compound, and further strengthen our discovery platform. It’s just one more example of how we are harnessing modern technology to uncover life-changing therapies from nature.”
Terrain’s novel technology uniquely complements KC Bio’s own AI-powered unEarthRx technology platform, built to yield high-quality leads from nature five times faster than convention. Together, the technologies offer an extraordinary opportunity to take drug discovery to a new level.
“Terrain’s cutting-edge spatial biology platform will allow us to visualize the effects of KCB-100 with extraordinary detail, generating robust, actionable data that is essential for KC Bio’s advancement of KCB-100,” said Dr. Je Lee, Co-Founder and CEO, Terrain Life Science. “We’re inspired by KC Bio’s approach to drug discovery and are proud to support their innovative pipeline. Together, we aim to generate new scientific understanding that can accelerate the development of treatments for neurodegenerative diseases.”
Leadership at KC Bio and Terrain view this partnership as a strong foundation for deeper collaboration, bringing together highly complementary omics technologies to accelerate innovation. Both organizations are committed to advancing next-generation scientific approaches that can drive meaningful progress in the development of novel therapies.
Kapoose Creek Bio (KC Bio) is a Canadian biotechnology company revolutionizing the discovery of drugs from nature with unprecedented speed and scale, using AI and advanced multiomic technologies. With a world-unique biological library and a team of globally recognized scientists, KC Bio is dedicated to mapping the world’s natural chemistry, uncovering its incredible therapeutic potential, and addressing some of the most urgent medical challenges of our time.
Terrain Life Science is a precision medicine intelligence company redefining the landscape of precision medicine. For too many patients, treatment selection is a heartbreaking process of trial-and-error because current technologies fail to reflect the complex topology of their disease. Terrain’s platform combines spatial proteomics with AI to map cellular targets in unprecedented depth. Find Terrain online at https://www.terrainlifescience.com.